Catalyst Pharmaceuticals, Inc. (CPRX) News
Filter CPRX News Items
CPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CPRX News Highlights
- CPRX's 30 day story count now stands at 17.
- Over the past 27 days, CPRX's stories per day has been in a clear downtrend, falling by about 0.32 per 3 days.
- The most mentioned tickers in articles about CPRX are RARE, ARAV and DRUG.
Latest CPRX News From Around the Web
Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to Kick-Off Rare Disease Day on February 28, 2022 CORAL GABLES, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medic |
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton Myasthenic Syndrome CommunityCORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the launch of a podcast called LEMS Aware. Produced by Catalyst, the podcast, created |
10 Best Robinhood Stocks To Buy Right NowIn this article, we discuss 10 best Robinhood stocks to buy right now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Robinhood Stocks To Buy Right Now. Stock trading applications like Robinhood Markets, Inc. (NASDAQ:HOOD) are becoming more popular as tech-enabled disruption sweeps the world of finance. […] |
Here's Why Momentum in Catalyst (CPRX) Should Keep goingCatalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year. |
Analysts Just Shipped A Substantial Upgrade To Their Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) EstimatesCelebrations may be in order for Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) shareholders, with the analysts... |
Catalyst Pharmaceuticals expects Q4 revenues to rise 24% Y/Y; provides 2022 outlookCatalyst Pharmaceuticals (NASDAQ:CPRX) reported preliminary Q4 revenue estimates and 2022 outlook. Q4 2021 total revenues expected to increase ~24% Y/Y to ~$38M. Consensus Revenue Estimate for Q4 is $36.90M. Full year 2021 total revenues expected to rise by 18% Y/Y to ~$141M. Consensus Revenue Estimate for 2021 is $138.31M. Year end 2021... |
Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare ActivityCatalyst Pharmaceuticals Inc (NASDAQ: Full story available on Benzinga.com |
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update2021 Total Revenues Estimated at $141 Million, Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million, Representing YoY Growth of 38% to 45% Recently Regained Orphan Drug Exclusivity in the U.S. for Amifampridine to Treat LEMS Entering 2022 with a Strong Cash Position of Approximately $191 Million and No Funded Debt Poised to Acquire Products, Pipeline and/or Companies in 2022 CORAL GABLES, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical |